Galantamine treatment in outpatients with mild Alzheimer's disease.

Richarz, U; Gaudig, M; Rettig, K; Schauble, B

Richarz, U; Gaudig, M; Rettig, K; Schauble, B.

Affiliation

Richarz U; Global Medical Affairs, GMAL Established Products, Janssen Global Services LCC, Titusville, NJ, USA.

Acta Neurol Scand ; 129(6): 382-92, 2014 Jun.

Article in En | MEDLINE | ID: mdl-24461047

Subject(s)

Alzheimer Disease/drug therapy; Galantamine/therapeutic use; Nootropic Agents/therapeutic use; Activities of Daily Living; Aged; Cognition/drug effects; Female; Follow-Up Studies; Galantamine/adverse effects; Humans; Male; Nootropic Agents/adverse effects; Outpatients; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome

Key words

ADAS-cog; Alzheimer's disease; Bayer Activity of Daily Living Scale; Neuropsychiatric Inventory; adverse effects; galantamine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nootropic Agents / Alzheimer Disease / Galantamine Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Acta Neurol Scand Year: 2014 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google